Puriblood Medical Co., Ltd. (6847.TWO)

TWD 101.5

(-1.93%)

EBITDA Summary of Puriblood Medical Co., Ltd.

  • Puriblood Medical Co., Ltd.'s latest annual EBITDA in 2023 was -44.01 Million TWD , down -272.86% from previous year.
  • Puriblood Medical Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -5 Million TWD , down -8.59% from previous quarter.
  • Puriblood Medical Co., Ltd. reported an annual EBITDA of 26.01 Million TWD in 2022, up 184.29% from previous year.
  • Puriblood Medical Co., Ltd. reported an annual EBITDA of -30.8 Million TWD in 2021, down -992.2% from previous year.
  • Puriblood Medical Co., Ltd. reported a quarterly EBITDA of -5 Million TWD for 2024 Q2, down -8.59% from previous quarter.
  • Puriblood Medical Co., Ltd. reported a quarterly EBITDA of -8.82 Million TWD for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Puriblood Medical Co., Ltd. (2023 - 2019)

Historical Annual EBITDA of Puriblood Medical Co., Ltd. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -44.01 Million TWD -272.86%
2022 26.01 Million TWD 184.29%
2021 -30.8 Million TWD -992.2%
2020 3.46 Million TWD 116.17%
2019 -15.75 Million TWD 0.0%

Peer EBITDA Comparison of Puriblood Medical Co., Ltd.

Name EBITDA EBITDA Difference
BIONET Corp. 147.09 Million TWD 129.923%
DIVA Laboratories, Ltd. 100.31 Million TWD 143.877%
Genetics Generation Advancement Corp. 50.6 Million TWD 186.982%
Welgene Biotech Co.,Ltd. 26.83 Million TWD 264.016%
TFBS Bioscience Inc. 64.15 Million TWD 168.611%